Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity
Authors:
- 29 October 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 94 (1117) , 20200696
Abstract
Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been increased. We present our preliminary results on the clinical utilization of MRI-guided adaptive radiotherapy (MRgRT) for prostate cancer patients with the workflow, dosimetric parameters, toxicities and prostate-specific antigen (PSA) response. Methods: 50 prostate cancer patients treated with ultra-hypofractionation were included in the study. Treatment was performed with intensity-modulated radiation therapy (step and shoot) technique and daily plan adaptation using MRgRT. The SBRT consisted of 36.25 Gy in 5 fractions with a 7.25 Gy fraction size. The time for workflow steps was documented. Patients were followed for the acute and late toxicities and PSA response. Results: The median follow-up for our cohort was 10 months (range between 3 and 29 months). The median age was 73.5 years (range between 50 and 84 years). MRgRT was well tolerated by all patients. Acute genitourinary (GU) toxicity rate of Grade 1 and Grade 2 was 28 and 36%, respectively. Only 6% of patients had acute Grade 1 gastrointestinal (GI) toxicity and there was no Grade ≥ 2 GI toxicity. To date, late Grade 1 GU toxicity was experienced by 24% of patients, 2% of patients experienced Grade 2 GU toxicity and 6% of patients reported Grade 2 GI toxicity. Due to the short follow-up, PSA nadir has not been reached yet in our cohort. Conclusion: In conclusion, MRgRT represents a new method for delivering SBRT with markerless soft tissue visualization, online adaptive planning and real-time tracking. Our study suggests that ultra-hypofractionation has an acceptable acute and very low late toxicity profile. Advances in knowledge: MRgRT represents a new markerless method for delivering SBRT for localized prostate cancer providing online adaptive planning and real-time tracking and acute and late toxicity profile is acceptable.Keywords
This publication has 34 references indexed in Scilit:
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 yearsRadiation Oncology, 2013
- Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patientsActa Oncologica, 2012
- Characterizing Interfraction Variations and Their Dosimetric Effects in Prostate Cancer RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesRadiation Oncology, 2011
- Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladderRadiotherapy and Oncology, 2007
- Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancerRadiotherapy and Oncology, 2006
- A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRTInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 GyJournal of Clinical Oncology, 2006
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006